Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5363 plus paclitaxel in advanced or metastatic breast cancer
jRCT2080222418Phase 2
- Sponsor
- AstraZeneca
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capivasertib in breast cancer (3 arms), sponsored by AstraZeneca.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080222418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222418.